Centric Health Resources launches unique marketing campaign to reach out to patients

With an ongoing dedication to improving the quality of life for people nationwide with rare, orphan, and ultra-orphan, chronic genetic disorders, Centric Health Resources, Inc. (www.centrichealthresources.com) announces the launch of its ground-breaking, direct response marketing campaign, which utilizes MP3 players loaded with informative podcasts about Centric’s patient-centered approach to all phases of its specialty drug programs.

“We want our new marketing efforts to match our philosophy of ‘patients first, last, and always,’” says Centric CEO Craig Kephart. “So we’re employing a livelier, visually fun, and friendly attitude on all fronts to reflect this patient-centric approach.”

The most recent podcast answers such questions as: Is your risk strategy ready for the Food and Drug Administration? Is your reimbursement plan ready to synch with payers? Does your pricing reflect your channel costs? Delivered by Kephart, the discussion informs listeners about how Centric is working to reinvigorate reimbursement strategies by setting the right price up front -- and how this approach instills confidence in every stakeholder.

In the second of the series of podcasts, Kephart discusses best practices for ultra-orphan drug launches, distribution, and management. All podcasts can be found at: http://www.centrichealthresources.com/thebook/index.html

Centric also unveiled its newly redesigned Website to dramatically announce the new direction Centric is taking on behalf of its patients and their families, providers, and manufacturers.

The Website also features a page dedicated to the recent 2009 Centric Ultra-Orphan Conference with options that include speaker videos, an event summary, and downloadable presentations. Visit: http://www.centrichealthresources.com/conference_summary.aspx

“We have taken a revolutionary approach in our marketing campaign and Website to make a compelling metaphorical statement about how Centric has effectively narrowed the vast space that previously existed between drug manufacturers, patients with rare and chronic genetic disorders, providers, and payers,” Kephart says. “By actively exploring the specialized health care needs of individuals who suffer from orphan diseases, we want to chart a new path to link an estimated 25 million Americans with the therapeutic advancements they deserve. Basically, we’re putting patients at the center of our universe.”